UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Alimentary pharmacology & therapeutics, 2021-11, Vol.54 (9), p.1150-1161

2021

Volltextzugriff (PDF)

Oral insulin: A history of ambition, failure and data torturing

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.940-942

2023

Volltextzugriff (PDF)

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.1011-1023

2023

Volltextzugriff (PDF)

Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply

Alimentary pharmacology & therapeutics, 2021-12, Vol.54 (11-12), p.1498-1498

2021

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins

Diabetes, obesity & metabolism, 2023-12, Vol.25 (12), p.3817-3825

2023

Volltextzugriff (PDF)

Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion

Diabetes, obesity & metabolism, 2024-01, Vol.26 (1), p.215-223

2024

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

Diabetes, obesity & metabolism, 2022-09, Vol.24 (9), p.1819-1828

2022

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study

Diabetes, obesity & metabolism, 2022-04, Vol.24 (4), p.713-721

2022

Volltextzugriff (PDF)

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Diabetes, obesity & metabolism, 2022-05, Vol.24 (5), p.806-815

2022

Volltextzugriff (PDF)

Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1351-1360

2023

Volltextzugriff (PDF)

Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1140-1147

2018

Volltextzugriff (PDF)

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study

Diabetes therapy, 2020-07, Vol.11 (7), p.1591-1603

2020

Volltextzugriff (PDF)

Better glycaemic control with BioChaperone glargine lispro co‐formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes

Diabetes, obesity & metabolism, 2019-07, Vol.21 (7), p.1570-1575

2019

Volltextzugriff (PDF)

Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study

Diabetes, obesity & metabolism, 2017-04, Vol.19 (4), p.489-495

2017

Volltextzugriff (PDF)

Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity

Diabetes, obesity & metabolism, 2023-03, Vol.25 (3), p.832-843

2023

Volltextzugriff (PDF)

Euglycaemic glucose clamp: what it can and cannot do, and how to do it

Diabetes, obesity & metabolism, 2016-10, Vol.18 (10), p.962-972

2016

Volltextzugriff (PDF)

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

British journal of clinical pharmacology, 2021-05, Vol.87 (5), p.2303-2320

2021

Volltextzugriff (PDF)

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study

Diabetes, obesity & metabolism, 2022-02, Vol.24 (2), p.196-203

2022

Volltextzugriff (PDF)

Pharmacological Intervention in Type 2 Diabetes Mellitus - A Pathophysiologically Reasoned Approach?

Current diabetes reviews, 2016-12, Vol.12 (4), p.429-439

2016

Volltextzugriff (PDF)

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial

The lancet. Diabetes & endocrinology, 2019-03, Vol.7 (3), p.179-188

2019

Volltextzugriff (PDF)

Oral Insulin Reloaded: A Structured Approach

Journal of diabetes science and technology, 2014-05, Vol.8 (3), p.458-465

2014

Volltextzugriff (PDF)

Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial

Diabetes care, 2021-06, Vol.44 (6), p.1361-1367

2021

Volltextzugriff (PDF)

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

The journal of clinical endocrinology and metabolism, 2013-05, Vol.98 (5), p.E867-E871

2013

Volltextzugriff (PDF)

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects

Clinical pharmacokinetics, 2019-11, Vol.58 (11), p.1497-1504

2019

Volltextzugriff (PDF)

Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Diabetes care, 2021-06, Vol.44 (6), p.1361

2021

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Endocrinology & Metabolism
(22)
Diabetes
(19)
Humans
(19)
Insulin
(18)
Diabetes Mellitus, Type 2 - Drug Therapy
(13)
Diabetes Mellitus
(12)
Pharmacokinetics
(12)
Glucose
(9)
Male
(9)
Original
(9)
Adult
(8)
Pharmacodynamics
(8)
Double-Blind Method
(7)
Female
(7)
Middle Aged
(7)
Pharmacology & Pharmacy
(7)
Glucagon
(6)
Hypoglycemic Agents - Adverse Effects
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Oral insulin: A history of ambition, failure and data torturing

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply

Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins

Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes

Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study

Better glycaemic control with BioChaperone glargine lispro co‐formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes

Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study

Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity

Euglycaemic glucose clamp: what it can and cannot do, and how to do it

Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study

Pharmacological Intervention in Type 2 Diabetes Mellitus - A Pathophysiologically Reasoned Approach?

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial

Oral Insulin Reloaded: A Structured Approach

Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects

Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Suchergebnisse filtern